文献速递肾移植

尿液CXCL9在移植肾炎症谱系中的诊断价值

Urinary CXCL9 Across the Spectrum of Kidney Allograft Inflammation.
PubMed 文献 · Kidney Int Rep · 2026-07-11

研究基于3181对活检-尿液标本,评估尿液CXCL9与肌酐比值(uCXCL9:Cr)在Banff 2022分类下对移植肾炎症的诊断价值。结果显示uCXCL9:Cr随炎症表型严重程度梯度升高,独立关联各炎症类别,并提升多分类AUC(开发队列0.797→0.831,验证队列0.801→0.821)。

要点

  • uCXCL9:Cr在无特异病变最低,混合炎症模式最高,随微血管和肾小管间质活动评分升高。
  • uCXCL9:Cr独立关联Banff 2022各炎症类别,RRR范围1.68-3.44。
  • 加入uCXCL9:Cr可提升诊断AUC并可能减少不必要的活检。

核心结论

  • uCXCL9反映现代Banff表型下的活动性移植肾炎症,提供超越标准变量的诊断信息,支持其用于指导活检决策和监测,有待前瞻性验证。

研究设计与样本

  • 分析开发队列(921例患者,1341次活检)和独立外部验证队列(917例患者,1840次活检)共3181对活检-尿液标本。

主要发现

  • uCXCL9:Cr中位数在无特异病变为4.55 ng/mmol,抗体介导表型为15.14,急性T细胞介导排斥为46.11,混合炎症模式为53.18-134.05(P < 0.001)。
  • uCXCL9:Cr随微血管和肾小管间质活动评分升高而增加(所有P < 0.001)。
  • 多变量多项分析中,uCXCL9:Cr独立关联每个炎症类别(RRR范围1.68-3.44;所有P ≤ 0.004)。
  • 加入uCXCL9:Cr后多分类AUC在开发队列从0.797升至0.831,验证队列从0.801升至0.821(均P = 0.001)。
  • 决策曲线分析显示纳入uCXCL9可能减少不必要的活检。

临床怎么用

  • uCXCL9:Cr可作为无创标志物辅助评估移植肾炎症活动度,优化活检决策和监测策略。

局限性

  • 结论需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Kidney allograft inflammation spans a heterogeneous spectrum of phenotypes defined by the Banff 2022 classification. We assessed whether urinary C-X-C motif chemokine ligand 9 (uCXCL9) normalized to creatinine (uCXCL9:Cr) captures inflammatory burden across this spectrum and provides incremental diagnostic utility beyond standard variables. METHODS: We analyzed 3181 biopsy-urine pairs from a development cohort (1341 biopsies from 921 patients) and an independent external validation cohort (1840 biopsies from 917 patients). Associations with Banff 2022 diagnostic categories were evaluated using multinomial logistic regression with stability-based selection. Incremental performance was assessed using the Hand & Till multiclass area under the curve (AUC) and decision curve analysis. RESULTS: uCXCL9:Cr demonstrated a graded increase across the inflammatory spectrum, with lowest levels in biopsies without specific lesions (median 4.55 ng/mmol), intermediate levels in antibody-mediated phenotypes (15.14), higher levels in acute T cell-mediated rejection (TCMR; 46.11), and the highest levels in mixed inflammatory patterns (53.18-134.05; P < 0.001). Levels increased proportionally with microvascular and tubulointerstitial activity scores (all P < 0.001). In multivariable multinomial analyses, uCXCL9:Cr was independently associated with each inflammatory category across the Banff 2022 spectrum (relative risk ratio [RRR] range: 1.68-3.44; all P ≤ 0.004). Addition of uCXCL9:Cr increased multiclass AUC from 0.797 to 0.831 in the development cohort and from 0.801 to 0.821 in the validation cohort (both P = 0.001). Incorporation of uCXCL9 was associated with a potential reduction in unnecessary biopsies in decision-curve analyses. CONCLUSION: uCXCL9 reflects active kidney-graft inflammation across modern Banff phenotypes and provides clinically meaningful diagnostic information beyond standard variables, supporting its potential to inform biopsy decisions and monitoring in kidney transplant recipients, pending prospective validation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cortes Garcia E, Wellekens K, Tinel C, et al. Urinary CXCL9 Across the Spectrum of Kidney Allograft Inflammation. Kidney Int Rep. 2026. PMID: 42621113. doi:10.1016/j.ekir.2026.106702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。